We at the university assistance and help them as best as we can. I myself have actually been working in early drug discovery in Dortmund for 20 years, and it is especially crucial to me that at some time society also makes money from our work. The road from fundamental research to a real drug is long, that makes me all the better that we have taken another essential action in the shape of this spin-off. Now that KyDo has likewise secured its first institutional capital, work can really get underway.
Which experiences from the cooperation with TU Dortmund University had a special influence on your spin-off?
Our spin-off has profited, of course, from the university’s support– through the Center for Entrepreneurship & Transfer along with TU capital. Along with distinguished global venture capital funds, the Venture Capital Seed Fund of TU Dortmund University is part of the current round of financing so that the university is now also taking part in our start-up as an investor. The university and PROvendis also assisted us to prepare the complex license and participation contracts. This assistance was vital to ensuring that the innovation transfer procedure was water tight and legally certified. For many years, we have had the ability to gather a wealth of experience at TU Dortmund University vis-à-vis academic spin-offs and significantly enhance procedures together with our partners.
Why is Dortmund such a favorable environment for KyDo?
Over the ins 2015, Dortmund has become a strong area for drug discovery: Together with LDC, Taros, limit Planck Institute of Molecular Physiology and the Leibniz Proving Ground for Working Environment and Human Elements (IfADo), this likewise consists of networks such as the Drug Discovery Center Dortmund (DDHD) and the Zentrum für integrierte Wirkstoffforschung (ZIW) (“Center for Integrated Drug Discovery”). We likewise work closely with the West German Cancer Center at Essen University Hospital and, together with the University of Duisburg-Essen, belong to the North Rhine-Westphalian research study network CANTAR, which focuses on innovative drug discovery in oncology. Another example is the across the country TACTIC consortium, which is moneyed by German Cancer Help and whose goal is to establish novel tumor treatments. Here, too, expertise from Dortmund plays a key role.
This develops a really fertile environment for KyDo, and we have actually already shown in the past that start-ups working on targeted cancer therapies are able to grow here– the most current example is PearlRiver Bio GmbH, which I also co-founded and which we effectively sold in 2021.